NVG 444
Alternative Names: NVG-444; SR-Ab-8Latest Information Update: 24 Jan 2023
At a glance
- Originator NovalGen
- Class Antihaemorrhagics; Bispecific antibodies
- Mechanism of Action Factor VIII stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haemophilia A
Most Recent Events
- 10 Dec 2022 Early research in Haemophilia A in United Kingdom (Parenteral) before December 2022 (NovalGen pipeline, January 2023)
- 10 Dec 2022 Preclinical trials in Haemophilia A in United Kingdom (Parenteral)
- 10 Dec 2022 Pharmacodynamics and adverse events data from preclinical studies in Haemophilia A presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)